Association of Haemostatic and Inflammatory Biomarkers with Nephropathy in Type 1 Diabetes Mellitus
Table 2
Association between haemostatic and inflammatory biomarkers with chronic kidney disease in type 1 diabetic patients.
Variable
Odds ratio (95% confidence interval) unadjusted
Odds ratio (95% confidence interval) adjusted
INF-γ
1.021 (1.008–1.035)
0.002
1.025 (1.010–1.040)
0.001
TNF-α
1.006 (1.002–1.011)
0.002
1.008 (1.003–1.013)
0.001
IL-6
1.224 (1.051–1.426)
0.009
1.304 (1.091–1.559)
0.004
IL-10
1.002 (1.000–1.003)
0.018
1.003 (1.001–1.004)
0.003
VWF
1.003 (1.001–1.004)
<0.001
1.003 (1.001–1.004)
<0.001
ADAMTS13 antigen
1.005 (1.002–1.007)
<0.001
1.005 (1.002–1.007)
<0.001
ADAMTS13 activity
1.030 (1.009–1.051)
0.004
1.034 (1.011–1.057)
0.004
VWF/ADAMTS13 antigen
0.667 (0.490–0.907)
0.010
0.702 (0.501–0.984)
0.040
VWF/ADAMTS13 activity
1.129 (1.031–1.236)
0.009
1.125 (1.017–1.244)
0.022
ADAMTS13 activity/antigen
7 × 10−11 (4 × 10−16–1 × 10−5)
<0.001
7 × 10−11 (4 × 10−16–1 × 10−5)
<0.001
D-Dimer
1.008 (1.004–1.012)
<0.001
1.008 (1.004–1.012)
<0.001
Data was evaluated by bivariate and multivariate logistic regression analysis and are presented as odds ratio (95% confidence interval) per unit increase of exposure variable. Variables included in multivariate logistic regression analysis were previously associated with chronic kidney disease in bivariate logistic regression analysis () and consisted of use of angiotensin converting enzyme inhibitor (ACEi) or angiotensin antagonist, use of statin, and use of acetylsalicylic acid (AAS).
